Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer

被引：5
|
作者：
Telli, Melinda L.
Timms, Kirsten
Reid, Julia E.
Neff, Christopher
Abkevich, Victor
Gutin, Alexander
Sangale, Zaina
Illiev, Diana
Jones, Joshua Timothy
Hennessy, Bryan
Lanchbury, Jerry S.
Mills, Gordon B.
Hartman, Anne-Renee
Ford, James M.
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Myriad Genet Inc, Salt Lake City, UT USA
[3] Royal Coll Surgeons Ireland, Med Oncol, Dublin 2, Ireland
[4] Beaumont Hosp, Dublin 9, Ireland
[5] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.1018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1018
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer
    Melinda L. Telli
    Jessica Hellyer
    William Audeh
    Kristin C. Jensen
    Shikha Bose
    Kirsten M. Timms
    Alexander Gutin
    Victor Abkevich
    Rebecca N. Peterson
    Chris Neff
    Elisha Hughes
    Zaina Sangale
    Joshua Jones
    Anne-Renee Hartman
    Pei-Jen Chang
    Shaveta Vinayak
    Richard Wenstrup
    James M. Ford
    [J]. Breast Cancer Research and Treatment, 2018, 168 : 625 - 630
  • [2] Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer
    Telli, Melinda L.
    Hellyer, Jessica
    Audeh, William
    Jensen, Kristin C.
    Bose, Shikha
    Timms, Kirsten M.
    Gutin, Alexander
    Abkevich, Victor
    Peterson, Rebecca N.
    Neff, Chris
    Hughes, Elisha
    Sangale, Zaina
    Jones, Joshua
    Hartman, Anne-Renee
    Chang, Pei-Jen
    Vinayak, Shaveta
    Wenstrup, Richard
    Ford, James M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (03) : 625 - 630
  • [3] Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple negative and BRCA1/2 mutation-associated breast cancer (BC)
    Telli, M. L.
    Jensen, K. C.
    Abkevich, V.
    Hartman, A-R
    Vinayak, S.
    Lanchbury, J.
    Gutin, A.
    Timms, K.
    Ford, J. M.
    [J]. CANCER RESEARCH, 2012, 72
  • [4] Homologous recombination deficiency (HRD) score predicts response to standard neoadjuvant chemotherapy in patients with triple negative or BRCA1/2 mutation-associated breast cancer
    Telli, Melinda L.
    Audeh, William
    Jensen, Kirstin C.
    Bose, Shikha
    Timms, Kirsten
    Gutin, Alexander
    Abkevich, Victor
    Lanchbury, Jerry
    Neff, Chris
    Hughes, Elisha
    Sangale, Zaina
    Jones, Joshua
    Wenstrup, Richard
    Hartman, Anne-Renee
    Chang, Pei-Jen
    Vinayak, Shaveta
    Ford, James M.
    [J]. CANCER RESEARCH, 2015, 75
  • [5] Homologous recombination deficiency (HRD) status to predict the efficacy and prognosis of platinum-based neoadjuvant chemotherapy in patients with triple-negative breast cancer.
    Jin, Xuan
    Chen, Minyan
    Chen, Hanxi
    Chen, Lili
    Lin, Yuxiang
    Wu, Long
    Tang, Ganghuai
    Li, Weiwei
    Huang, Zhan
    Li, Qian
    Zhu, Changbin
    Guo, Wenhui
    Fu, Fangmeng
    Wang, Chuan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
    Telli, Melinda L.
    Timms, Kirsten M.
    Reid, Julia
    Hennessy, Bryan
    Mills, Gordon B.
    Jensen, Kristin C.
    Szallasi, Zoltan
    Barry, William T.
    Winer, Eric P.
    Tung, NadineM.
    Isakoff, Steven J.
    Ryan, Paula D.
    Greene-Colozzi, April
    Gutin, Alexander
    Sangale, Zaina
    Iliev, Diana
    Neff, Chris
    Abkevich, Victor
    Jones, Joshua T.
    Lanchbury, Jerry S.
    Hartman, Anne-Renee
    Garber, Judy E.
    Ford, James M.
    Silver, Daniel P.
    Richardson, Andrea L.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3764 - 3773
  • [7] Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance
    Afghahi, Anosheh
    Timms, Kirsten M.
    Vinayak, Shaveta
    Jensen, Kristin C.
    Kurian, Allison W.
    Carlson, Robert W.
    Chang, Pei-Jen
    Schackmann, Elizabeth
    Hartman, Anne-Renee
    Ford, James M.
    Telli, Melinda L.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3365 - 3370
  • [8] Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis
    Chai, Yue
    Chen, Yujie
    Zhang, Di
    Wei, Yuce
    Li, Zhijun
    Li, Qiao
    Xu, Binghe
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
  • [9] The status of homologous recombination deficiency is a potential biomarker for platinum-based chemotherapy in triple-negative breast cancer
    Chen, Yimeng
    Wang, Xue
    Du, Feng
    Yue, Jian
    Si, Yiran
    Cui, Lina
    Zhang, Bei
    Xu, Binghe
    Yuan, Peng
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [10] Efficacy of platinum-based neoadjuvant chemotherapy in early triple-negative breast cancer according to germline BRCA mutation
    Bae, S. J.
    Jang, J. S.
    Kook, Y.
    Baek, S. H.
    Kim, J. H.
    Kim, M. J.
    Lee, S. E.
    Moon, S.
    Kim, J. H.
    Ahn, S. G.
    Jeong, J.
    [J]. BREAST, 2023, 68 : S59 - S60
12345